Quest Diagnostics (DGX)
(Delayed Data from NYSE)
$170.85 USD
+3.44 (2.05%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $170.84 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth D Momentum B VGM
Fundamental Charts
About Market Cap
As of the previous market close, Quest Diagnostics Incorporated has a market cap of $18.72B, which represents its share price of $167.41 multiplied by its outstanding shares number of 111.82M. As a large-cap company, DGX's shareholders are generally exposed to less risk than shareholders of small and mid-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
DGX 170.85 +3.44(2.05%)
Will DGX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DGX
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Why Quest Diagnostics (DGX) is a Top Growth Stock for the Long-Term
DGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Danaher Q2 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
Quest Diagnostics Beats Q2 Earnings & Revenue Estimates, Stock Rises
Quest Diagnostics (DGX) Beats Q2 Earnings and Revenue Estimates
Other News for DGX
Athena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene ...
Quest Diagnostics Inc (DGX) Unveils Advanced Genetic Test for Ataxia Using PacBio's PureTarget ...
Quest Diagnostics (DGX) Sees Price Target Reduced by Piper Sandler
Quest Diagnostics price target lowered by $10 at Piper Sandler, here's why
Options Corner: Quest Diagnostics' Post-Earnings Digestion Drama Opens A Science-Backed Opportunity